halbert said...
Which suggests that the common model is wrong. That Prostate cells do not progressively go from "normal" to G3, then to G4, then to G5. That, instead, somehow prostate cells go from normal to nasty in one step.
I don't know what "common model" you think exists, but the current consensus is that Gleason pattern 3 cells don't somehow mutate into 4's or 5's. Rather, in some people due to their biologic conditions, new pattern 4 or 5 cells might grow. That's different than going "from normal to nasty."
BTW, the "nasty" version I referred to are generally, more technically, the neuroendocrine strain.
halbert said...
Is it possible to be "pro-screening" and "anti-overtreatment" at the same time?
Let me briefly (a whitepaper could be written on each of these, but I’ll be brief) tell you what I am pro/con on:
I am in support of a new prostate cancer grading system recommended this year by Dr. Jon Epstein of Johns Hopkins—unarguably one of the world’s leading PC pathologists—to replace the current Gleason system. If you are not familiar with it, read the New PC Infolink summary link below, but essentially it enables a return to a simpler system in which Grade 1 is the least aggressive and Grade 5 is the most aggressive. Too many people unnecessarily panic when they hear they have a “6” (ie., 3+3) out of a scale of 10…6 simply does not “sound” like it is the lowest possible score (although it is). Read this: http://prostatecancerinfolink.net/2015/06/10/toward-a-new-prostate-cancer-grading-system-step-1/
I am:
• Anti-mass PSA screening of men at any age in the absence of an informed decision by the patient following a ”patient education” discussion with his physician about
the uncertainties, risks and potential benefits of PSA testing; which would also include an explanation about
prostate cancer risk categories, and recommended actions for each category.
But
• Pro-baseline testing starting at age 40 of all men (or for men of any age who have not yet had a PSA test), only after informed decision (described above), with subsequent action (such as follow-up testing) individually determined based on the baseline (and/or subsequent testing) outcome.
I am anti-overtreatment (frankly, who wouldn’t be), but I believe this is primarily going to be accomplished through a combination of an effective “patient education” program (partially described above) and through proper incentivizing of physicians for well-being care (largely via active surveillance programs for well-selected men). I believe that in such an approach, the default for an “educated” favorable-risk man will be AS, followed by curative treatment if indicators cross the threshold.